Short Interest in Braveheart Bio, Inc. (NASDAQ:BRVE) Expands By ?

Braveheart Bio, Inc. (NASDAQ:BRVE) saw a large increase in short interest during the month of August. As of August 14th, there was short interest totaling 847,773 shares, an increase of ? from the July 30th total of 0 shares. Based on an average daily volume of 650,680 shares, the short-interest ratio is presently 1.3 days. Approximately 1.2% of the shares of the stock are sold short.

Insider Activity at Braveheart Bio

In other Braveheart Bio news, Director Orbimed Advisors Llc bought 1,940,000 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $34,920,000.00. Following the completion of the transaction, the director directly owned 11,901,826 shares in the company, valued at approximately $214,232,868. The trade was a 19.47% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Erez Chimovits bought 1,940,000 shares of the stock in a transaction on Friday, August 7th. The shares were acquired at an average cost of $18.00 per share, with a total value of $34,920,000.00. Following the purchase, the director owned 11,901,826 shares of the company’s stock, valued at approximately $214,232,868. This represents a 19.47% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 8,751,942 shares of company stock worth $157,534,956 in the last three months.

Braveheart Bio Price Performance

Shares of BRVE stock opened at $27.44 on Friday. Braveheart Bio has a twelve month low of $24.61 and a twelve month high of $32.00.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Braveheart Bio to a “hold” rating in a research report on Saturday, August 15th.

About Braveheart Bio

We are a clinical?stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB?1893, is a next-generation oral small?molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non?obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.